Invega, also known by its generic name paliperidone, is approved for the treatment of schizophrenia in adults and adolescents aged 12 years and older [1][2]. It is also indicated for the treatment of schizoaffective disorder in adults [2].
What is Schizophrenia and Schizoaffective Disorder?
Schizophrenia is a chronic mental disorder that affects how a person thinks, feels, and behaves. Individuals with schizophrenia may seem like they have lost touch with reality, which can be distressing for them and their families. Symptoms can include hallucinations, delusions, disorganized thinking, and a reduction in emotional expression [3].
Schizoaffective disorder is a chronic mental health condition that includes symptoms of schizophrenia, such as hallucinations or delusions, and symptoms of a mood disorder, like depression or mania [4]. The mood disorder symptoms must be present for a significant portion of the illness's duration for a diagnosis of schizoaffective disorder [4].
How Does Invega Work?
Paliperidone is an atypical antipsychotic medication [1]. It is believed to work by affecting dopamine and serotonin neurotransmitter systems in the brain [1]. By modulating these neurotransmitter levels, Invega can help to manage the symptoms associated with schizophrenia and schizoaffective disorder, such as hallucinations, delusions, and disordered thinking [1][2].
What Forms of Invega Are Available?
Invega is available in several formulations, including oral tablets and long-acting injectable suspensions [1][5]. The extended-release oral tablets are taken once daily, while the injectable forms provide longer-term treatment, with dosing intervals that can range from monthly to every three months, depending on the specific product [5].
What Are the Potential Side Effects of Invega?
Common side effects associated with Invega use can include weight gain, somnolence, dizziness, headache, and extrapyramidal symptoms such as tremor or akathisia [1]. More serious potential side effects may include tardive dyskinesia, a movement disorder; neuroleptic malignant syndrome, a rare but potentially fatal reaction; and metabolic changes like hyperglycemia and dyslipidemia [1][2]. Individuals taking Invega should be monitored for these effects by their healthcare provider [2].
When Does Invega's Patent Protection End?
Patent information for Invega is complex and involves multiple patents covering the drug and its various formulations. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals. Generally, the patent landscape for a drug can extend beyond the initial patent by considering new formulations or delivery methods [6].
Who Manufactures Invega?
Invega is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
Can Other Companies Make Generic Versions of Invega?
Once patent protections and any associated market exclusivities expire, other pharmaceutical companies can seek approval from regulatory agencies to manufacture and market generic versions of paliperidone [6]. The availability of generic alternatives can influence the pricing of the medication.
What Clinical Trials Support Invega's Use?
Clinical trials have demonstrated the efficacy of paliperidone in reducing the symptoms of schizophrenia and schizoaffective disorder [1][2]. These studies typically involve comparing the drug's effects against a placebo or an active comparator in patient populations diagnosed with these conditions.
How is Invega Administered?
Invega can be administered orally as extended-release tablets taken once daily [1]. Long-acting injectable formulations are also available, which are administered by a healthcare professional at specific intervals, such as monthly (Invega Sustenna) or every three months (Invega Trinza and Invega Hafyera) [5].
What Are the FDA's Approved Indications for Invega?
The U.S. Food and Drug Administration (FDA) has approved Invega for the treatment of schizophrenia in adults and adolescents (12 years and older) and for the treatment of schizoaffective disorder in adults [1][2].
Sources:
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021715s059,022070s026,022497s023lbl.pdf
- https://www.janssen.com/sites/default/files/invegasustennatrinzahafyerapi.pdf
- https://www.nimh.nih.gov/health/topics/schizophrenia
- https://www.nimh.nih.gov/health/topics/schizoaffective-disorder
- https://www.invegahcp.com/
- https://drugpatentwatch.com/